Precigen Triple-Gene Information

Precigen Triple-Gene, a majority-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), is a clinical stage gene therapy company focused on advancing targeted, controllable, and multigenic gene therapies for the treatment of complex cardiovascular diseases. The Company's lead product is a non-viral investigational gene therapy candidate that drives expression of three candidate effector genes involved in heart failure. Learn more about Precigen Triple-Gene at www.precigen.com/triple-gene/.